Journal of Cutaneous Immunology and Allergy (Dec 2022)
Development of tinea corporis in a Japanese patient with atopic dermatitis under treatment with upadacitinib in a real‐world clinical setting: Possible contribution of the suppression of Th17
Abstract
We present a rare case of a patient with AD who developed tinea corporis during upadacitinib treatment in a real‐world clinical setting. We hypothesized that the suppressive effect of Th17 immunity by upadacitinib possibly has contributed to the development of tinea corporis.
